newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//Benzinga
Interim results from the Phase 2 portion of the HexAgon study showed that 44% of patients receiving the INBRX-106 combination achieved a confirmed objective response, compared to 21.4% in the control group.
INBRX-106 combination achieved a 44% objective response rate versus 21.4% in the control group.
KEY POINTS
Three patients in the INBRX-106 arm achieved a complete radiographic response in the Phase 2 trial.
Inhibrx will start Phase 3 trials of INBRX-106 in the third quarter of 2026.
A perioperative non-small cell lung cancer study of INBRX-106 will begin later this quarter.
Inhibrx plans to test INBRX-106 with vaccines, T-cell engagers, and CAR-T therapies.
Combination Therapy Shows Deeper Tumor Reduction
The interim results from the Phase 2 portion of the HexAgon study showed that 44% of patients receiving the INBRX-106 combination achieved a confirmed objective response, compared to 21.4% in the control group.
The data represent a significant increase in confirmed responses, highlighting the potential of INBRX-106 as a treatment option.
Responding patients in the combination arm demonstrated deeper tumor reductions overall, with the majority achieving target lesion shrinkage exceeding 50%; notably, three patients achieved a complete radiographic response.
Inhibrx Expands INBRX-106 Development Pipeline
The company expects progression-free survival data from the Phase 2 portion of the HexAgon study in the fourth quarter of 2026 and plans to start the Phase 3 portion in the third quarter of 2026.
The clinical-stage biopharmaceutical company also plans to expand evaluation of INBRX-106 into broader indications aimed at improving checkpoint inhibitor efficacy.
A perioperative non-small cell lung cancer study is expected to begin later this quarter, reflecting the company's view that OX40 agonism may offer the strongest curative potential in earlier-stage disease, where immune systems remain more responsive.
The company is also preparing to move into first-line metastatic NSCLC, with studies targeted to begin in 2027.
Company Plans Additional Combination Studies
Beyond checkpoint inhibitor combinations, it plans to evaluate INBRX-106 alongside therapies that may benefit from T-cell costimulation, including vaccines, T-cell engagers, and CAR-T therapies.
INBX Stock Price Activity: Inhibrx Biosciences shares were up 3.95% at $139.66 at the time of publication on Monday, according to Benzinga Pro data.
Photo via Shutterstock